Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433014 | 0.83 | LMNA (0.70) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL7610124 | 0.81 | LMNA (0.61) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL1415999 | 0.79 | LMNA (0.69) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL31530746 | 0.78 | LMNA (0.58) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL8911780 | 0.78 | LMNA (0.62) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL2362178 | 0.77 | LMNA (0.56) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL13859959 | 0.76 | MAPT (0.71) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL13859943 | 0.76 | MAPT (0.58) | LMNAMAPTKDM4ECYP3A4NCOA1 | |
| SCHEMBL2047789 | 0.76 | CYP3A4 (0.62) | LMNAMAPTKDM4ECYP3A4MEN1 | |
| SCHEMBL18743109 | 0.76 | LMNA (0.55) | LMNAMAPTKDM4ECYP3A4NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | EDUSA PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-1901775-B1 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1901775-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | Jerini AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1539181-B1 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1795196-A2 | Method of treating lower urinary tract disorders | Dynogen Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070060652-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2004084881-A1 | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084879-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING SMOOTH MUSCLE MODULATORS AND ALPHA-2-DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004066990-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-0213293-B1 | 11-Substituted 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1992-01-02 | — | — | EP | disclosed |
| EP-0126366-B1 | QUATERNARY SALTS OF DIBENZO(1,4)DIAZEPINONE, PYRIDO-(1,4)BENZODIAZEPINONE, PYRIDO(1,5)BENZODIAZEPINONE DERIVATIVES AND PHARMACOLOGICAL ACTIVITY THEREOF | DOMPE' FARMACEUTICI S.p.A. (IT) | 1988-12-14 | — | — | EP | disclosed |
| EP-0125607-B1 | PYRIDO(1,5)BENZODIAZEPINONE DERIVATIVES AND PHARMACOLOGICAL ACTIVITIES THEREOF | DOMPE' FARMACEUTICI S.p.A. (IT) | 1988-10-26 | — | — | EP | disclosed |
| US-4594190-A | Quaternary salts of dibenzo[1,4]diazepinones, pyrido-[1,4]benzodiazepinones, pyrido[1,5]benzodiazepinones with antiulcer, antisecretory, spasmolytic and antimusarinic activities | DOMPE' FARMACEUTICI S.P.A. (IT) | 1986-06-10 | — | — | US | disclosed |
| US-4556653-A | ANTISECRETORY, ANTIULCER AND ANTISPASMODIC AGENTS | DOMPE' FARMACEUTICA S.P.A. (IT) | 1985-12-03 | — | — | US | disclosed |
| EP-0126366-A2 | Quaternary salts of dibenzo(1,4)diazepinone, pyrido-(1,4)benzodiazepinone, pyrido(1,5)benzodiazepinone derivatives and pharmacological activity thereof | DOMPE' FARMACEUTICI S.p.A. (IT) | 1984-11-28 | — | — | EP | disclosed |
| EP-0125607-A2 | Pyrido(1,5)benzodiazepinone derivatives and pharmacological activities thereof | DOMPE' FARMACEUTICI S.p.A. (IT) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | CACNB2, RYR2, FABP2 | LMNA 3209/4885MAPT 2937/4885KDM4E 4198/4885 |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | BDKRB2, BDKRB1, F2R | LMNA 3313/4885MAPT 3933/4885KDM4E 3659/4885 |
| US-20070060652-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | GABRB2, GABRB3, GABRB1 | LMNA 1728/4885MAPT 2775/4885KDM4E 3557/4885 |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | LMNA 1728/4885MAPT 2775/4885KDM4E 3557/4885 |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | GABRB2, GABRB3, GABRB1 | LMNA 1854/4885MAPT 3038/4885KDM4E 3559/4885 |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | LMNA 1728/4885MAPT 2775/4885KDM4E 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.